Can exercise reduce treatment toxicity during the initial phase of testosterone suppression in prostate cancer patients?

Not Applicable

Recruiting

• Conditions: Prostate Cancer; Cancer - Prostate

• Registration Number: ACTRN12612000097842
• Lead Sponsor: Edith Cowan University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-01-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 124

Inclusion Criteria

Men initiating androgen supression therapy (AST) for the treatment of prostate cancer

Exclusion Criteria

1) Prior exposure to AST (e.g. those re-initiating AST from intermittent programs)
2) Established metastatic bone disease
3) Established osteoporosis
4) Taking medications known to affect bone metabolism (e.g. bisphosphonates),
5) Any acute illness, musculoskeletal, cardiovascular or neurological disorder that could inhibit a participant's
ability to participate in the exercise program or put them at risk of injury or illness.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Areal Bone Mineral Density (BMD): BMD of the hip, lumbar spine as well as whole body bone mineral content (BMC, g) will be assessed by dual-energy X-ray absorptiometry.[Baseline, 3 months, 6 months and 12 months]